Biogen Wants To Reduce Amevive Copay, Adds Pharmacy Distribution
Executive Summary
Biogen is pursuing initiatives to reduce the copay burden for patients taking the psoriasis agent Amevive
You may also be interested in...
Biogen Closing Gap On Amevive Reimbursement: Pre-Authorization At 30%
The percentage of Amevive patients needing prior authorization for the psoriasis biologic has shrunk to 30%, Biogen Idec CEO Jim Mullen told investors Jan. 12 at the J.P. Morgan health care cconference in San Francisco
Biogen Closing Gap On Amevive Reimbursement: Pre-Authorization At 30%
The percentage of Amevive patients needing prior authorization for the psoriasis biologic has shrunk to 30%, Biogen Idec CEO Jim Mullen told investors Jan. 12 at the J.P. Morgan health care cconference in San Francisco
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive